Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of CDZ173 in Patients With Primary Sjögren's Syndrome

Next Previous
Search
Trial Profile

A Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of CDZ173 in Patients With Primary Sjögren's Syndrome

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 06 Jan 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Leniolisib (Primary)
  • Indications Sjogren's syndrome
  • Focus Adverse reactions; Proof of concept; Therapeutic Use
  • Sponsors Novartis Pharmaceuticals

    • Most Recent Events

    • 09 Nov 2021 Results assessing possible options for alternative responder definitions that indicate the optimal balance of sensitivity and specificity from dour trials ((NCT02962895, NCT02775916; NCT02291029; NCT02149420) presented at the ACR Convergence 2021
    • 16 Jun 2018 Primary endpoint (EULAR Sjgrens Syndrome Patient Reported Intensity (ESSPRI) change from baseline) has not been met, according to results presented at the 19th Annual Congress of the European League Against Rheumatism.
    • 16 Jun 2018 Results presented at the 19th Annual Congress of the European League Against Rheumatism.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top